The purpose of this report is to provide a summary of the outputs and outcomes achieved by EASL during the year 2017 related to the overall objectives of the EASL Mission and Vision.

<table>
<thead>
<tr>
<th>CONTENTS</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Notes from the Secretary General and Vice-Secretary</td>
<td>4</td>
</tr>
<tr>
<td>2. EASL Governance</td>
<td>6</td>
</tr>
<tr>
<td>a. Mission</td>
<td>6</td>
</tr>
<tr>
<td>b. Governing Board</td>
<td>6</td>
</tr>
<tr>
<td>c. Ethics Committee</td>
<td>8</td>
</tr>
<tr>
<td>d. Concerted Action Groups</td>
<td>8</td>
</tr>
<tr>
<td>3. EASL Office</td>
<td>12</td>
</tr>
<tr>
<td>4. Membership</td>
<td>13</td>
</tr>
<tr>
<td>5. Science and Education</td>
<td>14</td>
</tr>
<tr>
<td>a. Events</td>
<td>14</td>
</tr>
<tr>
<td>i. ILC 2017</td>
<td></td>
</tr>
<tr>
<td>ii. HCC summit</td>
<td></td>
</tr>
<tr>
<td>iii. NAFLD summit</td>
<td></td>
</tr>
<tr>
<td>iv. Monotherapeutic conference</td>
<td></td>
</tr>
<tr>
<td>v. EASL-AASLD joint meeting</td>
<td></td>
</tr>
<tr>
<td>vi. Schools and EASL-AASLD joint masterclass</td>
<td></td>
</tr>
<tr>
<td>vii. EASL endorsed and sponsored events</td>
<td></td>
</tr>
<tr>
<td>b. eLearning</td>
<td>28</td>
</tr>
<tr>
<td>i. LiverTree</td>
<td></td>
</tr>
<tr>
<td>ii. EASL Grand Round Series</td>
<td></td>
</tr>
<tr>
<td>iii. Conference debriefs</td>
<td></td>
</tr>
<tr>
<td>iv. iLiver</td>
<td></td>
</tr>
<tr>
<td>v. EASL HCV advisor app</td>
<td></td>
</tr>
<tr>
<td>c. Publications</td>
<td>31</td>
</tr>
<tr>
<td>i. Journal of Hepatology</td>
<td></td>
</tr>
<tr>
<td>ii. Clinical Practice Guidelines</td>
<td></td>
</tr>
<tr>
<td>6. Fellowships and Research support</td>
<td>34</td>
</tr>
<tr>
<td>a. Fellowships</td>
<td>34</td>
</tr>
<tr>
<td>b. Mentorship</td>
<td>38</td>
</tr>
<tr>
<td>c. Scientific Research (Registry Grants)</td>
<td>39</td>
</tr>
<tr>
<td>7. Policy and Public Affairs</td>
<td>40</td>
</tr>
<tr>
<td>a. EASL Brussels Office</td>
<td>40</td>
</tr>
<tr>
<td>b. EU-funded Projects</td>
<td>41</td>
</tr>
<tr>
<td>i. ALIVER</td>
<td></td>
</tr>
<tr>
<td>ii. LITMUS</td>
<td></td>
</tr>
<tr>
<td>8. Acknowledgements</td>
<td>43</td>
</tr>
<tr>
<td>9. Finance</td>
<td>44</td>
</tr>
</tbody>
</table>
EASL remains at the forefront of hepatology with its annual meeting, The International Liver Congress™ (ILC). At ILC 2017 in Amsterdam, over 9,000 experts in hepatology, infectious medicine, gastroenterology, surgery and a broad range of other medical specialties, and nurses attended from 124 different countries from all over the globe to listen to the latest liver research. More than 2,500 authors submitted abstracts from their scientific work to the congress, of which approximately 60% was selected following rigorous peer-review (each abstract is reviewed by 4 independent reviewers). The congress also harbours a rich educational programme, covering all areas of liver disease, as well as an increasing number of interactive sessions to foster academic and clinical advances. Alongside our flagship meeting, the Journal of Hepatology remains at the top tier of journals in gastroenterology, with a steady impact factor around 12.5. The Clinical Practice Guidelines (CPGs) remain, without a doubt, one of the most important communications from our association. Over the past eight years, EASL has published over 25 CPGs, including four in 2017; The role of endoscopy in primary sclerosing cholangitis, the diagnosis and management of patients with primary biliary cholangitis, the management of hepatitis B virus infection, the management of acute (fulminant) liver failure. However, beside these well-known pillars of EASL programming, the 2017 calendar was full of other EASL activities, including:

- **February 2017** - a basic school in liver immunology, now including an emphasis on hands-on practical training
- **February 2017** - the now annual HCC summit, becoming a leading “melting pot” for science and education in liver oncology
- **June 2017** - a monothematic conference on cholangiocarcinoma in health and disease: from basic science to novel treatments, a huge success demonstrating the growing relevance of rare liver diseases
- **September 2017** - a joint EASL-AASLD meeting on definition, therapeutic advances and clinical endpoints in alcoholic liver disease and alcoholic hepatitis – one of a series of meetings to be run together with AASLD to cover the need for debate and consensus on aspects related to drug development in evolving areas of hepatology
- **November 2017** - the first of an annual series of NALFD summits, to foster one of the major emerging topics in hepatology along the successful model of the HCC summit
- **November 2017** - a clinical school of hepatology on controversies in end-stage liver disease, built along the much revised “flipped classroom” model of EASL educational events
- **December 2017** - the first EASL-AASLD joint masterclass, established to nurture development and networking amongst emerging leaders in hepatology in both Europe and the USA.

EASL also tries to foster and enhance our sub-communities and aims to involve through endorsement and recommendation to other liver-related meetings. In 2017 a total of 15 events were supported in this way. EASL also sponsored three non-EASL events. Importantly, EASL will continue to promote research and mobility for young investigators through a wide range of fellowships and mentorship, now including a major enhancement of existing offers. All fellowships were reviewed throughout 2017 and now include an increased level of funding as well as a stronger affiliation with host institutions who currently oversee the financial management. The three revised individual fellowship programmes on offer are:

- **Juan Rodes Ph.D. Studentships**
- **Sheila Sherlock Post-Graduate Fellowships**
- **Andrew K. Burroughs Short-Term Fellowships**

Successful EU applications in the liver research area has been a major emphasis of EASL and was part of the motivation for EASL establishing a Brussels office in 2015. EASL now offers not only financial support, but also active project engagement as to the communication and dissemination packages inherent to such applications. Furthermore, to foster the monitoring of developments in hepatology and establish base-line natural-history data for a variety of understudied conditions, EASL will continue to grow its registry grants programme, which has become hugely popular with a total of 14 registries funded over the last 4 years.
EASL is a medical association dedicated to pursuing excellence in liver research, clinical practice of liver disorders, and in providing education to all those interested in hepatology. While the roots of the association were founded in Europe in 1966, EASL continues to engage globally with all stakeholders in the liver field wherever they are based, in the aim to spread knowledge and expertise in best practices and the latest scientific breakthroughs in hepatology. 

EASL’s mission is to be the home of hepatology so that all who are involved with treating liver disease can realise their full potential to cure and prevent it. The purpose of the association is to promote communication between European workers interested in the liver and its disorders. In particular, the association shall:

1. Promote research concerning the liver.
2. Promote education of physicians, scientists and public awareness of liver diseases and their management.
3. Act as an advisor to European and national health authorities concerning liver diseases, provision of clinical services and the need for research funding.
4. Foster European multicentre controlled trials.
5. Facilitate scientific exchange.
6. Facilitate participation of young investigators at its meetings.

B. GOVERNING BOARD

The EASL Governing Board is composed of 12 members; 11 scientific experts and the Executive Director of EASL. The EASL Governing Board is dedicated to the pursuit of excellence in hepatology, liver research and the clinical practice of liver disorders. The Governing Board has the following duties:

1. To manage the business of the Association.
2. To carry out the resolutions taken at the Business Meeting.
3. To represent the Association. The Secretary General has joint signatory power together with the Treasurer or any other person entrusted with the management and representation by the Governing Board.
4. To attend to all matters which are not delegated to or reserved for another functional body of the Association pursuant to the law or the Articles of Association.
5. To accept new Ordinary Members, Corresponding Members and Trainee Members.
6. In case of considerable financial gains, the Governing Board prepares proposals for approval at the Business Meeting for the destination of parts of these gains. These destinations should serve purposes that are in agreement with the aims of the Association.
7. To prepare proposals for alterations of the Articles of Association if necessary.
8. To decide about matters concerning the EASL membership fee.
9. To select and propose to the Business Meeting the name of the Editor-in-Chief of the Journal of Hepatology.
C. ETHICS COMMITTEE

The principal role of the Ethics Committee is to support the Governing Board to promote the highest standards of ethics in the field of hepatology and educate members on ethical issues. These tasks are accomplished by proposing and administering conflict of interest policies to the EASL Governing Board, Journal of Hepatology Editors and Editorial Board, the Executive Director as well as members of EASL Clinical Practice Guidelines panels, EASL committees and task forces, consultants, faculty, and others acting on behalf of EASL.

In addition, the Ethics Committee will review the disclosures of financial or non-financial relationships (hereafter referred to as “disclosures”), which potentially lead to conflicts of interest among the candidates for the panels charged with authoring EASL Clinical Practice Guidelines, to eliminate the potential for real or perceived bias which might undermine the integrity of the guidelines.

Furthermore, the Ethics Committee will respond to complaints made by EASL members, governmental authorities or regulatory agencies about the conduct of any Governing Board member and members of any other EASL board or EASL representative.

The Ethics Committee consists of five members who are independent from the Governing Board membership. One member, elected by the Ethics Committee, performs the role of the chair. Members are proposed by the Ethics Committee for approval by the Business Meeting. Each member serves for three years.

The Ethics Committee tables guidelines for avoidance of conflicts of interest by the EASL leadership, assesses eligibility of Clinical Practice Guideline panels and monitors adherence to the code of conduct. Candidate membership of the panels is proposed by the Governing Board.

D. CONCERTED ACTION GROUPS

The EASL Concerted Action Groups (CAGs) were implemented to improve collaboration between scientists from a range of disciplines sharing common specialist interests. To date, there are four EASL CAGs and one Focus Group:

- **BASIC SCIENCE CAG**
- **PUBLIC HEALTH CAG**
- **YOUNG INVESTIGATORS CAG**
- **NURSE CAG**
- **EASTERN EUROPE FOCUS GROUP**
The Eastern Europe Focus Group advises the EASL Governing Board on their activities and collaboration opportunities in Eastern European countries. The group meets once or twice a year.

The Eastern Europe Focus Group aims to:
• Listen to and understand the needs of scientists and healthcare providers in these countries
• Improve the presence and awareness of EASL in Eastern European countries
• Advise the EASL Governing Board on the organisation of specific initiatives
• Facilitate the relationship with existing EASL members from Eastern Europe and to improve collaboration and cooperation initiatives.

iii. YOUNG INVESTIGATORS CAG

The Young Investigators CAG works on the diverse programmes offered to Young Investigators during The International Liver Congress™, notably the Young Investigator Forum and Young Investigator Seminar.

It aims to:
• Build an active and dynamic community of Young Investigators
• Promote and facilitate discussion and exchange of information both online and offline
• Host an exclusive social networking event for Young Investigators at The International Liver Congress™
• Provide opportunities to contribute to the development of smartphone and tablet apps
• Encourage other Young Investigators to become EASL members.

EASL GOVERNING BOARD REPRESENTATIVE: Annalisa Berzigotti Switzerland

Young Investigators Concerted Action Group Members:
Rodrigo Liberal  United Kingdom
Upkar Gill     United Kingdom
Giacomo Germani  Italy
Femke Heindryckx  Sweden

iv. NURSE CAG

The Nurse CAG was launched in 2017 and aims to improve communication within the European nurse community and to advise the EASL Governing Board on topics of interest.

The Nurse CAG aims to:
• Work collaboratively on the research and quality agenda
• Develop links with affiliated liver nursing fora, committees, societies across Europe
• Develop programmes, including the Nurses and Associates Forum at The International Liver Congress™
• Work jointly with the EASL Office to have a sustainable Membership programme for nurses
• Collaborate in strengthening liver nursing across Europe with joint funding and links to ongoing medical projects
• Work together to raise and improve the experience of care, and to deliver a quality service to people with liver disease.

EASL GOVERNING BOARD REPRESENTATIVE: Annalisa Berzigotti Switzerland

Nurse Concerted Action Group Members:
Michelle Clayton  United Kingdom
Lynda Greenslade  United Kingdom
Nathalie Goutte  France
Kristine Hørr  Denmark
Kathrin Hui  Switzerland
Neus Llarch  Spain
Markus Reiss  Germany

v. EASTERN EUROPE FOCUS GROUP

The Eastern Europe Focus Group advises the EASL Governing Board on their activities and collaboration opportunities in Eastern European countries. The group meets once or twice a year.

The Eastern Europe Focus Group aims to:
• Listen to and understand the needs of scientists and healthcare providers in these countries
• Improve the presence and awareness of EASL in Eastern European countries

EASL GOVERNING BOARD REPRESENTATIVE: Frank Tacke Germany

Eastern Europe Focus Group Members:
Liana Gheorghe  Romania
Goran Jankovic  Serbia
Jerzy Jaroszewicz  Poland
Marina Maevskaya  Russia
Francesco Negro  Switzerland
Alexander Nersesov  Kazakhstan
Marieta Simonova  Bulgaria

EASL GOVERNING BOARD REPRESENTATIVE: Annalisa Berzigotti Switzerland

Nurse Concerted Action Group Members:
Michelle Clayton  United Kingdom
Lynda Greenslade  United Kingdom
Nathalie Goutte  France
Kristine Hørr  Denmark
Kathrin Hui  Switzerland
Neus Llarch  Spain
Markus Reiss  Germany
In April 1966, EASL began as a small group of 70 hepatologists from 15 European countries who came together to share expertise in best medical practices. Now with over 4,400 members from all over the world, EASL is an influential international organisation. It attracts the foremost hepatology experts as members and has an impressive track record in promoting research in liver disease, supporting wider education, and promoting changes in European liver policy.

EASL gathers those interested in the liver from all over the world. At EASL we project into the future and look forward to continuing our efforts in 2018 and to providing you with the latest developments by inspiring the hepatology community during The International Liver Congress™ in Paris and other EASL activities throughout the year.
The International Liver Congress™ is the annual EASL meeting and the flagship event in our educational calendar. Every year in April, scientific and medical experts from a broad range of fields including hepatology, gastroenterology, internal medicine, cell biology, transplant surgery, infectious diseases, microbiology and virology, pharmacology, pathology and radiology, and imaging come together from around the world to learn about the latest in liver research. Specialists share recent data, present studies, and findings, and discuss the hottest topics in liver disease. In 2017, the annual congress attracted 9,011 delegates and 200 media representatives from all over the world making this a truly international networking opportunity.

The Congress Scientific Programme was composed of:

- 2 State of the Art lectures
- 1 Postgraduate Course: A multidisciplinary approach to patients with liver disease
- 1 Basic Science Seminar: Hepatic regenerative medicine
- 1 Postgraduate Course on liver transplant
- 4 General sessions
- 1 Late Breaker session
- 3 Clinical Practice Guidelines sessions
- 21 Parallel sessions
- 22 Early Morning Workshops
- 16 Symposia
- 10 Joint Workshops
- 5 Grand Rounds
- 25 Oral ePoster sessions
- 1 Best Poster summary
- 20 Poster Tours
- 2 EU and EU funded projects sessions
- 2 Public Health sessions on HCV/HBV elimination
- 2 Fellowship and Registry Grant sessions
- 2 Young Investigator sessions
- 1 Nurses & Associates Forum
- 2 Highlights from the Literature sessions
- 4 Hands-on Ultrasound sessions
- 3 Sonography courses
- 1 General Assembly

Amsterdam, The Netherlands, 19-23 April 2017
In the Skills Learning Centre congress delegates had the opportunity to look, learn, ask questions, and test tools and devices used for procedures under the tutelage of experts in the field. This new hands-on activity was presented in a relaxed and friendly atmosphere during which delegates could talk with experts and ask an array of questions related to the practice of interventions in patients with liver disease.

The Skills Learning Centre increased awareness of diagnostic and therapeutic techniques and offered delegates the possibility to examine their own knowledge and skills. Open at specific times during the general opening hours of the Congress, the Skills Learning Centre was divided into three components:

- Non-invasive diagnostic methods
- Invasive methods: evaluation and procedures
- Emerging therapies

New in 2017 – The Skills Learning Centre

During the Congress, Key Opinion Leaders, appointed by the EASL Governing Board, toured the paper posters with groups of delegates to discuss interesting data and research findings with the respective presenters.

In 2017, 98 posters were presented over the course of three days throughout 28 tours. These tours were conducted by colour-coded topic relating to specialties.

The scientific programme was designed to distinguish between specialties and fields, enabling visitors to make informed choices on sessions of interest based on the scientific content to be presented rather than just on the type of session being held.

EASL thanks its sponsors and participating companies for their generous support: http://2017.ilc-congress.eu/exhibition-industry/acknowledgements/

EASL applies for accreditation from the European Accreditation Council for Continuing Medical Education (EACCME) for all its educational activities.

During the Congress, Key Opinion Leaders, appointed by the EASL Governing Board, toured the paper posters with groups of delegates to discuss interesting data and research findings with the respective presenters.
Another success was the recording and distribution of the “Best of ILC 2017”. During the congress week, experts discussed the latest in their field:

- Best of Alcoholic and Metabolic Liver Disease by Prof. Elisabetta Bugianesi and Dr Ramon Bataller
- Best of Cirrhosis and Complications by Prof. Emmanuel Tsochatzis and Dr Joan Genesca Ferrer
- Best of Liver Tumours by Profs. Bruno Sangro and Peter Schirmacher
- Best of Viral Hepatitis by Profs. Heiner Wedemeyer and Fabien Zoulim

These extensive summaries of the latest advances were made available for all on the EASL Europe YouTube channel and on the LiverTree™, the EASL educational platform.

Recognition Awards

The first EASL Recognition Awardees were acknowledged in Vienna 2006. Over a decade later the tradition continues to recognise the scientists, the men and women, who write the history of our Association and progress the field of hepatology.

In 2017, EASL presented three recognition awards to Prof. Giorgia Mieli-Vergani, Prof. Gustav Paumgartner, and Prof. Kenjiro Wake for their major scientific contributions in the field of liver research.

EASL encourages Young Investigators (YIs) to be active in the field of hepatology and invites them to take part in The International Liver Congress™. A dedicated YI lounge was located beside the EASL booth allowing YIs to socialize and talk with members of the YI-CAG, to meet other YIs from different nationalities as well as find information about the EASL Masterclass, Mentorship and Fellowship programmes, upcoming Schools of Hepatology, and the Journal of Hepatology.

EASL also provides bursaries to the authors of the best-accepted abstracts to financially support young fellows to attend The International Liver Congress™.

Two years ago, to celebrate the 50th anniversary of EASL, the Young Investigator Concerted Action Group introduced an annual award specifically dedicated to young fellows. It was decided that every year, the EASL Governing Board and YI-CAG would select YI awardees based on their international liver research achievements to-date. The 2017 YI awards were presented to: Dr Evaggelia Liaskou and Dr Jean-Charles Nault.

The awardees were acknowledged during a General Session at The International Liver Congress™ in front of thousands of liver experts. They also presented their submitted abstract at the corresponding parallel session. EASL awardees receive a cash prize and are invited to publish a review in the Journal of Hepatology.
Every year, EASL offers national associations an opportunity to promote their society, national activities and events during The International Liver Congress™. In 2017, the following associations attended showcasing how active the hepatology field is in different locations around the world:

<table>
<thead>
<tr>
<th>National Associations Village</th>
</tr>
</thead>
<tbody>
<tr>
<td>Armenian Hepatological Forum</td>
</tr>
<tr>
<td>Austrian Society of Gastroenterology &amp; Hepatology</td>
</tr>
<tr>
<td>Belgian Association for the Study of the Liver</td>
</tr>
<tr>
<td>British Association for the Study of the Liver</td>
</tr>
<tr>
<td>Danish Society of Gastroenterology and Hepatology</td>
</tr>
<tr>
<td>Association Française pour l’Étude du Foie</td>
</tr>
<tr>
<td>German Association for the Study of the Liver</td>
</tr>
<tr>
<td>Hellenic Association for the Study of the Liver</td>
</tr>
<tr>
<td>Israel Association for the Study of the Liver</td>
</tr>
<tr>
<td>Associazione Italiana per lo Studio del Fegato</td>
</tr>
<tr>
<td>Polish Association for the Study of the Liver</td>
</tr>
<tr>
<td>Russian Scientific Liver Society</td>
</tr>
<tr>
<td>Hepatology Section of the Serbian Medical Association</td>
</tr>
<tr>
<td>Slovak Society of Hepatology - member of the Slovak Medical Association</td>
</tr>
<tr>
<td>Association Española para el Estudio del Hígado</td>
</tr>
<tr>
<td>Swiss Association for the Study of the Liver</td>
</tr>
<tr>
<td>Turkish Association for the Study of the Liver</td>
</tr>
<tr>
<td>Ukrainian Association for the Study of Liver diseases</td>
</tr>
</tbody>
</table>

Hepatocellular carcinoma (HCC), a malignant tumour of liver parenchymal cells, is a primary malignancy of the liver and occurs predominantly in patients with underlying chronic liver disease and cirrhosis. Currently, it ranks as the third leading cause of cancer deaths worldwide. The threat of HCC is expected to continue to grow in the coming years.

The second EASL HCC Summit took place in Geneva, Switzerland from 2-5 February 2017. The first EASL HCC Summit, hosted in 2014, was a great success, as EASL was able to effectively reach out to both scientists and clinicians with an interest in liver cancer, and following a similar winning formula, a broad and exciting scientific programme was devised for 2017; designed to be both informative and stimulating. The basic science programme on 2-3 February was centered around ‘The Hallmarks of Cancer’, and included talks from eminent scientists in the field of cancer, but with a focus on translational advances most relevant to patients with primary liver cancer. On the 4-5 February, this was immediately followed by a clinical programme, with state of the art talks on the most up to date management of patients with liver cancer. EASL will host the next HCC Summit from 01-03 March 2018 in Geneva, Switzerland.

Listen to Prof Massimo Colombo and Dr Alejandro Forner discuss the outcomes of the HCC summit’s clinical part. Find out the latest advances in Hepatocellular Carcinoma (HCC) research by watching Prof Tom Luedde and Dr Helen Reeves discussing the highlights.

On 4 February 2017, World Cancer Day took place at the same time as the EASL HCC Summit. To celebrate this occasion, EASL joined forces with the Union for International Cancer Control (UICC) to raise awareness. EASL created a liver cancer dedicated campaign; hundreds of persons joined the cause by wearing our green bracelets and sending us pictures to spread the word and raise awareness about HCC. Five members of the European Parliament wore the bracelets and the campaign received a round of applause when announced during the HepHIV 2017 conference held in Malta.

EASL applies for accreditation from the European Accreditation Council for Continuing Medical Education (EACCME) for all its educational activities.

EASL thanks its generous contributors for their support with the association’s various activities.

Nonalcoholic Fatty Liver Disease (NAFLD) is the leading cause of chronic liver disease not only in Western countries but also among developing countries. NAFLD is the most common liver disorder in Western countries. The prevalence in Western countries is estimated to be between 17-46% of the general population and approximately 20% of these individuals are likely to develop progressive liver disease (i.e., Nonalcoholic Steatohepatitis) which leads to liver fibrosis and cirrhosis.

As there is a growing need for the identification and development of new therapeutic options for NAFLD, EASL hosted its first NAFLD Summit in Rome, Italy, from 09-11 November 2017 where over 400 scientists, academia, and industry leaders met to discuss emerging therapeutic options and stimulated efforts to address key challenges across the NAFLD spectrum. The Summit covered the basic, translational, and clinical aspects of NAFLD, with a specific focus on novel drug targets and prognostic signature development.

#NAFLDsummit
Delegates: 402

Cholangiocytes not only have a barrier function, separating toxic bile from cells and structures in and around the bile ducts, but these cells are metabolically highly active and secrete copious amounts of water, electrolytes and bicarbonate. In addition, bile ducts harbor stem cells that are important for restoration and regeneration of the entire liver. Disturbances of any of these structures and functions may lead to disease manifestations and may underlie cholestatic liver disease.

Immunology and metabolism for long have been antipodes in the cause-and-effect discussion. It becomes more and more clear that immunological and toxic injury are closely related and amplify each other. New thinking is required that covers both fields. Although cholangiocytes reside deep in the liver, functionally these cells are at the cross roads between environment and self. Bacterial products from the gut are absorbed, secreted in bile where they affect cholangiocytes. Recent discoveries have led to insights and a better understanding of the close interaction between cholangiocytes and gut.

iv. CHOLANGIOCYTES IN HEALTH AND DISEASE: FROM BASIC SCIENCE TO NOVEL TREATMENTS
EASL Monothematic Conference
Oslo, Norway, 09-11 June 2017

EASL applies for accreditation from the European Accreditation Council for Continuing Medical Education (EACCME) for all its educational activities.
EASL thanks its generous contributors for their support with the association’s various activities.

The EASL Monothematic Conference on Cholangiocytes in health and disease; from basic science to novel treatments was held from 09-11 June 2017 in Oslo, Norway. The conference addressed major novel findings on the pathophysiology of biliary diseases and bile acid metabolism; implications of the gains in knowledge on the current and future clinical practice.

The conference served as the perfect venue for young scientists and clinicians to present their work and listen to key opinion leaders about what will be important in science and clinics in the years to come. The next EASL Monothematic Conference is entitled ‘Striving towards the elimination of HCV infection’ and will take place in Berlin, Germany from 02-03 February 2018.

#EASLmono
Delegates: 212

Listen to the debrief from the EASL Monothematic Conference by Dr. Jesus Banales, Prof. Dr. Peter L. Jansen, Prof. Nicholas F. Larusso, and Dr. Marco Marzioni.
EASL applies for accreditation from the European Accreditation Council for Continuing Medical Education (EACCME) for all its educational activities.
EASL thanks its generous contributors for their support with the association’s various activities.
A joint EASL-AASLD meeting took place in London, UK, from 30 September - 01 October. Around 170 delegates attended sessions in which experts from Europe and the U.S. strove to reach a consensus on how to treat the most prevalent cause of advanced liver disease and liver-related mortality in Western countries, Alcohol-related liver disease (ALD). The high mortality and prevalence of ALD and alcoholic hepatitis indicate a glaring need for therapies for the patient population. During the intensive two-day conference, delegates were invited to listen to presentations that revealed emerging data from clinical, translational, and basic sciences studies in ALD.

Excessive alcohol consumption is the cause of severe liver diseases such as liver cirrhosis, fatty liver, and cancer. Three decades of evidence resulted in determining that price, availability, and promotion are areas where consumption and harm are driven and therefore are the key areas to target for management at the societal level.
The EASL and AASLD Masterclass 2017 provided a unique educational collaboration for clinical scientists from leading academic medical institutions from both sides of the Atlantic. The scientific programme consisted of academic lectures, interactive sessions, individual meetings with tutors, as well as social events. Prior to the Masterclass, participants were assigned to working groups, and each group was led by a mentor and provided a task and guidance to complete a set of tasks. A series of abstracts were presented by Young Investigators on day two which was followed by the leadership skills workshop aimed at developing participants’ leadership and managerial capacities. Case-based discussions were held on viral hepatitis, metabolic and cholestatic, cirrhosis complications, and finally basic science. The final day covered ethics in science and the pros and cons of ‘alcohol and transplant’, finally ‘from non-A, non-B hepatitis to hepatitis C cure’. The two-day Masterclass offered a combination of scientific content with training in other areas presented in a workshop-style atmosphere.

Students: 23 Young Investigators

EASL thanks its generous contributors for their support with the association’s various activities.
**i. LiverTree™**

EASL continues to be at the forefront of hepatology research and pushes boundaries with new and exciting initiatives which provide an ideal platform. The EASL LiverTree™ is the only online medical educational resource designed by hepatologists for hepatologists. The platform hosts a variety of resources for researchers, students, physicians and nurses including webcasts filmed during EASL hosted meetings, conference de briefs, abstracts, indexed slides, and access to clinical practice guidelines.

**b. E-LEARNING**

45,571 indexed slides
8,423 abstracts from 52 EASL events
6,460 ePosters
2,365 webcasts
4,204 users

**ii. EASL GRAND ROUND SERIES AND CONFERENCE DEBRIEFS**

<table>
<thead>
<tr>
<th>Publication</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>February</td>
<td>Idiopathic non-cirrhotic portal hypertension Clinic Barcelona, Hospital Universitari</td>
</tr>
<tr>
<td>April</td>
<td>Acute on Chronic Liver Failure Padova University Hospital</td>
</tr>
<tr>
<td>June</td>
<td>Primary Sclerosing Cholangitis Hannover Medical School, Germany</td>
</tr>
<tr>
<td>August</td>
<td>Coagulation and Cirrhosis St Mary’s Hospital Campus, Imperial College London</td>
</tr>
<tr>
<td>August</td>
<td>Overcoming steatosis INSELSPITAL - Bern University Hospital</td>
</tr>
<tr>
<td>August</td>
<td>Hepatocellular carcinoma (HCC) University Medical Centre of the Johannes Gutenberg-Uni versity Mainz</td>
</tr>
<tr>
<td>August</td>
<td>Management of viral hepatitis Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico - University of Milan</td>
</tr>
</tbody>
</table>

**7 Grand Rounds**

<table>
<thead>
<tr>
<th>Publication</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>February</td>
<td>EASL HCC Summit 2017 - Clinical Debrief</td>
</tr>
<tr>
<td>February</td>
<td>EASL HCC Summit 2017 - Basic Science Debrief</td>
</tr>
<tr>
<td>April</td>
<td>Best of Viral Hepatitis from ILC2017</td>
</tr>
<tr>
<td>April</td>
<td>Best of Alcoholic and Metabolic Liver Disease from ILC2017</td>
</tr>
<tr>
<td>April</td>
<td>Best of Autoimmune and Cholestatic Liver Disease from ILC2017</td>
</tr>
<tr>
<td>April</td>
<td>Best of Cirrhosis and Complications from ILC2017</td>
</tr>
<tr>
<td>April</td>
<td>Best of Liver Tumours from ILC2017</td>
</tr>
<tr>
<td>April</td>
<td>Best of Nurses and Associates Forum from ILC2017</td>
</tr>
<tr>
<td>June</td>
<td>Monothematic conference: Cholangiocytes in health and disease</td>
</tr>
<tr>
<td>October</td>
<td>Debrief from EASL-AASLD Conference: Alcohol related Liver Disease</td>
</tr>
<tr>
<td>November</td>
<td>Debrief from EASL NAFLD Summit 2017</td>
</tr>
</tbody>
</table>
iii. iLIVER

iLIVER is a free app featuring content that is fully approved by independent expert reviewers and EASL Governing Board representatives. This interactive and dynamic app is designed exclusively for professional use, delivering instant medical information and clinical recommendations to medical experts (i.e., hepatologists, gastroenterologists and specialists in internal medicine) around the world. Once downloaded, the app content can be accessed without an internet connection making it a helpful reference tool that can be used at patient bedside. iLIVER is a resource that provides up-to-date clinical recommendations and information in over 26 different areas of liver disease.

26 Topics
4 Languages:
• Chinese
• English
• Russian
• Spanish
4,885 downloads in 2017

iv. EASL HCV ADVISOR APP

The HCV Advisor app is a tool provided free by EASL to health care professionals treating patients with hepatitis C. The app streamlines the selection of treatment. Based on the trusted EASL guidelines for treatment of Hepatitis C, clinicians can simply enter the patient and virus information and instantly review the appropriate treatment options available.

21 April (launch) - 31 December 2017
6,569 downloads

30
European Association for the Study of the Liver

31
European Association for the Study of the Liver

The Journal of Hepatology is the official Journal of EASL. Since its creation in 1985, the Journal has seen an impressive development and readership numbers are ever increasing. Over time, it has developed into one of the leading journals in the field, publishing the newest discoveries in hepatology. EASL membership includes free online access to the Journal of Hepatology.

iv. PUBLICATIONS

The Journal of Hepatology is the official Journal of EASL. Since its creation in 1985, the Journal has seen an impressive development and readership numbers are ever increasing. Over time, it has developed into one of the leading journals in the field, publishing the newest discoveries in hepatology. EASL membership includes free online access to the Journal of Hepatology. Announced in June 2017, the 2016 Journal of Hepatology impact factor was an exceptional 12.486, the highest the Journal of Hepatology has ever achieved, surpassing the 2014 IF score of 11.336. This marks EASL’s commitment to providing the liver community with the most up-to-date work and data of the highest quality.

This increase in the impact factor by 17% up to 12.486 is unprecedented, and I gratefully acknowledge the huge contribution of the authors who decide to publish their best papers in the Journal, the efforts of the whole Editorial team, the office in Geneva and the EASL Governing Board in getting us to this point.

Prof Rajiv Jalan, Editor-in-Chief

My vision for the Journal is to build on the excellent progress it has made over these past years and try and improve its Impact Factor. As importantly, however, I will aim to retain the impressive readability of the journal, build further on the science it publishes, grow its geo-political influence, and allow better interaction with the general public and patients to allow improvement of the perception of liver disease.

Prof Rajiv Jalan, Editor-in-Chief

With this impact factor, the official journal of EASL is ranked 2nd in the field of ‘Hepatology’ and 9th in ‘Gastroenterology and Hepatology’ (source: Clarivate Analytics), which is a continued testament to the Journal’s outstanding relevance in the field. The impact factor growth has been mirrored by the continuous increase in the number of submissions to the Journal and downloads from the different platforms where the Journal is hosted.

The Journal website www.journal-of-hepatology.eu provides maximum visibility by way of a user-friendly, state of the art hosting platform. The availability of mobile apps means that the Journal can be accessed using smartphones as well as tablets and is compatible with both iOS and Android devices.

My vision for the Journal is to build on the excellent progress it has made over these past years and try and improve its Impact Factor. As importantly, however, I will aim to retain the impressive readability of the journal, build further on the science it publishes, grow its geo-political influence, and allow better interaction with the general public and patients to allow improvement of the perception of liver disease.

Prof Rajiv Jalan, Editor-in-Chief
The first EASL Clinical Practice Guidelines (CPGs) were released in October 2008. CPGs are distributed via the Journal of Hepatology and define the use of diagnostic, therapeutic and preventive modalities, including non-invasive and invasive procedures in the management of patients with various liver diseases. They are intended to assist physicians and other healthcare providers as well as patients and interested individuals in the clinical decision-making process by describing a range of generally accepted approaches for the diagnosis, treatment and prevention of specific liver diseases.

In 2017, the Journal of Hepatology published the following EASL Clinical Practice Guidelines:

- Role of endoscopy in primary sclerosing cholangitis: European Society of Gastrointestinal Endoscopy (ESGE) and European Association for the Study of the Liver (EASL) Clinical Guideline
- EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis
- EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection
- EASL Clinical Practical Guidelines on the management of acute (fulminant) liver failure
6

FELLOWSHIPS AND
RESEARCH SUPPORT

a. FELLOWSHIPS

Post-Doctorate Fellowship
€40,000 awarded (up to three fellowships)

MAARTEN VAN DE KLUNDERT
Germany

LORENZO NEVI
Italy

Entry Level Fellowship
€30,000 awarded (up to three fellowships)

PUI-YUEN LEE
Spain

NORA CAZZAGON
Italy

DANIAL AFSHARZADEH
The Netherlands

DAME SHEILA SHERLOCK FELLOWSHIPS
TWO PROGRAMMES, ONE APPLICATION PERIOD:
30 SEPT - 30 NOV

www.easl.eu

European Association for the Study of the Liver
The aim of this fellowship is to encourage biomedical research in the field of paediatric and adult genetic cholestatic diseases sharing mutual disease-causing mechanisms.

An annual scientific award of €25,000 is provided to support a research-based project. The EASL Daniel Alagille Award is generously sponsored by CTRS laboratories and applications opened from 30 October – 30 November 2017.

In 2017, EASL enhanced its three current fellowship programmes to better reflect young investigators’ needs. The new fellowship programmes include:

- a student research fellowship programme directed at young graduates aiming to achieve a PhD in the field of basic, translational or clinical hepatology
- a short-term fellowship programme, directed at postgraduate investigators who intend to spend a limited amount of time at a foreign institution to accomplish a very focused research project
- a postdoctoral research fellowship programme, targeting the most promising newly qualified postgraduate researchers who wish to expand research fields and start developing their independent research careers.

From 2017 onwards awarded fellows will benefit from:

- Increased funding
- Longer training periods
- Mobility allowance
- Family allowance

---

**Physician-Scientists Fellowship**

€40,000 awarded

**EASL Daniel Alagille Award**

**2017 Awardee**

Dr Emma R. Andersson, Sweden

Department of Biosciences and Nutrition, Karolinska Institutet

**Consequences of missing a Notch in Alagille Syndrome: From basic mechanisms to testing therapies**

In 2017, EASL enhanced its three current fellowship programmes to better reflect young investigators’ needs. The new fellowship programmes include:

- a student research fellowship programme directed at young graduates aiming to achieve a PhD in the field of basic, translational or clinical hepatology
- a short-term fellowship programme, directed at postgraduate investigators who intend to spend a limited amount of time at a foreign institution to accomplish a very focused research project
- a postdoctoral research fellowship programme, targeting the most promising newly qualified postgraduate researchers who wish to expand research fields and start developing their independent research careers.

From 2017 onwards awarded fellows will benefit from:

- Increased funding
- Longer training periods
- Mobility allowance
- Family allowance

---

**Short-Term Training Fellowship Andrew K. Burroughs**

**JOHN RYAN**

United Kingdom

**KATRIN SCHÖLZEL**

United Kingdom

**MINH HUANG**

Vietnam

**AITOR ESPANZA BAQUER**

Spain

**Dr John Ryan and Katrin Schölzel at The International Liver Congress™ 2017 with Profs. Howard Thomas, Mauro Bernardi and Dr Barjesh Sharma.**

**Dr Emma Andersson receiving her prize at The International Liver Congress™ 2017 with Profs. Howard Thomas and Mauro Bernardi.**
The Mentorship Programme, launched in November 2012, was created as a means of enhancing scientific exchange and personal developmental relationships in which a more experienced and knowledgeable hepatologist would guide a Young Investigator through a crucial stage of their career path.

b. MENTORSHIP

- **Prof. Mario Strazzabosco**
  - Italy
  - Università di Milano-Bicocca & Yale School of Medicine

- **Dr. Emma R. Andersson**
  - Sweden
  - Department of Biosciences and Nutrition, Karolinska Institutet

- **Prof. Jean-François Dufour MD**
  - Switzerland
  - University Clinic Visceral Surgery and Medicine

- **Dr. Maria Chiara Sorbo**
  - Italy
  - University of Rome, Tor Vergata

- **Prof. Michael Trauner, MD**
  - Austria
  - Division of Gastroenterology and Hepatology, Medical University of Vienna

- **Dr. Vitor Magno Pereira**
  - Spain
  - Hospital Central do Funchal

EASL members interested in applying for Registry Grant funding must apply online. Applications are reviewed by the EASL Scientific Committee and the funded registry project should begin by June of the awarded year. Successful applicants are requested to attend The International Liver Congress™ in April when awarded projects are announced.

c. SCIENTIFIC RESEARCH (REGISTRY GRANT)

Devoted to understanding the liver and its related diseases, EASL promotes research and education through the sharing of research findings in hepatology. Funding provided by EASL helps to organise consortia groups dedicated to data gathering with a specific focus on liver disease. A minimum of €150,000 is awarded to support one or more consortia groups.

2017 Awarded Projects

<table>
<thead>
<tr>
<th>HEAD OF THE CONSORTIUM</th>
<th>PROJECT TITLE</th>
<th>COUNTRY OF RESIDENCE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prof. Christian Trautwein</td>
<td>Registry on Alpha 1-Antitrypsin Deficiency-Related Disease</td>
<td>Germany</td>
</tr>
<tr>
<td>Prof. Michael Heneghan</td>
<td>European Registry for Liver Disease in Pregnancy</td>
<td>United Kingdom</td>
</tr>
</tbody>
</table>

- Prof. Christian Trautwein receiving the EASL Registry Grant 2017 from Prof. Howard Thomas during The International Liver Congress™ 2017.
- Prof. Michael Heneghan receiving the EASL Registry Grant 2017 from Prof. Howard Thomas during The International Liver Congress™ 2017.
POLICY AND PUBLIC AFFAIRS

a. EASL OFFICE BRUSSELS

In 2017, the EU affairs team continued work on the advocacy priorities agreed within EASL. These include research and science policy, alcohol policy and awareness raising on liver diseases.

In research policy, the EU affairs team concentrated mainly on the Framework Programme, the EU’s programme for research funding. Throughout 2017, many important developments took place in this area.

To begin with, there was the Interim Evaluation of Horizon 2020, an EU-level initiative designed to take stock of the strengths and weaknesses of the current Framework Programme. We contributed to this process with an EASL response to the Commission consultation on the topic.

Furthermore, we worked closely together with the Alliance for Biomedical Research in Europe (BioMed Alliance) to convey biomedical researchers’ experiences with Horizon 2020 to policymakers. Several of our recommendations for improving Horizon 2020 made it into high-level documents, such as the European Parliament’s assessment of the current Framework Programme.

Throughout the past year, preparatory talks regarding Framework Programme 9 (FP9), the successor to Horizon 2020, started taking place at EU-level. Here too, the EU affairs team collaborated with the BioMed Alliance. For example, we initiated work on a position paper, summarizing our main recommendations for FP9. We hope to publicize the BioMed paper in the first quarter of 2018.

In 2017, the EU affairs team also laid the groundwork for an EASL application to the Marie Skłodowska-Curie COFUND scheme under Horizon 2020. If successful, this would enable EASL to set up a Marie Curie fellowship programme with co-financing from the European Commission.

A call for tender for grant writing services was issued in late December. EASL intends to submit the application in September 2019.

In addition to working on research policy we also focused on the prevention of liver disease. We continued to work on our campaign to tighten restrictions on the marketing of alcohol, food and sodas high in fats, salt and sugar in the proposal for a revised Audiovisual Media Services Directive (AVMSD). During the first reading of the proposal in the European Parliament in the first half of 2017 we contacted over 700 MEPs and met with culture attaches from several Member State to propose amendments to strengthen the Commission proposal. MEPs chose to maintain restrictions on alcohol marketing on advertising on video sharing platforms but the result on marketing for unhealthy food and drinks was less positive. As a result, EASL took part in the Estonian presidency conference on 30 October on unhealthy marketing of alcohol and supported the development of Council conclusions on the topic that were adopted in December 2017 at the Health and Social Affairs Council.

In November, EASL participated in the 5th Awareness Week on Alcohol Related Harm with our partners EUROCARE, ELPA, UEG and several others. The week focused on the theme of alcohol and cancer: www.awarh.eu. An event was held at the European Parliament on 23 November co-hosted by the MEP’s Against Cancer and MEP Friends of the Liver groups. On 24 November 2017, the Estonian Permanent Representation to the EU hosted a breakfast on alcohol and cancer for member state Health Attaches. Participants at both events called for stricter marketing regulations on alcohol, better labelling of products and the introduction of minimum unit pricing.

EASL continued to advocate on viral hepatitis throughout 2017. Incoming Governing Board member, Markus Cornberg, spoke on behalf of EASL at an event held under the Maltese Presidency of the EU on 2 February on HIV and Hepatitis C, sharing a panel with, inter alia, the WHO and the European Centre for Disease Control. On 23 March, EASL members Marieta Simonova and Jerzy Jaroszewicz spoke at an event hosted by the MEP Friends of the Liver group in the European Parliament on the specific challenges of treating HCV infection in central and eastern Europe, the Balkans and the Baltics. In June 2017 EASL was invited to join the revamped Civil Society Forum on HIV, TB and viral hepatitis. The CSF is an informal advisory body to the European Commission on these topics and members come from across the EU and neighbouring countries. The CSF meets twice year and is chaired by the EU Commission.

Rare diseases were also not neglected. In February 2017, the EU Commission launched 24 European Reference Networks, including one on rare liver diseases.

Finally, work finished at the end of November on the data collection for HEPAPHEALTH, an overview of liver disease and its determinants in 35 European countries. The full report will be launched at The International Liver Congress™ in 2018.

b. EU-FUNDED PROJECTS

Each year over 170,000 people die from liver cirrhosis in Europe. There are over one million deaths globally. Twenty-nine million EU citizens and 650 million people globally suffer from a chronic liver disease. The economic burden of liver disease in Europe has been estimated at over €15.8 billion per annum. The ALIVER Consortium has developed a novel and innovative liver dialysis machine that will help the liver to naturally regenerate or, where that does not prove possible, to keep patients alive and healthy until a donated liver becomes available. DIALIVE has been demonstrated to be effective in pre-clinical tests. The 24-participant ALIVER study is funded by a 66.4 million EU Horizon 2020 grant 733057, awarded to a consortium of 11 institutions from seven countries in Europe, including Yaqrit Ltd, a spinout company from University College London that is developing the DIALIVE device and IBM Ireland Ltd, which will be applying data analytics to identify new biomarkers that can help to optimise treatment protocols. In July 2017, the first patient in the ALIVER international trial of the DIALIVE system was recruited at the Royal Free Hospital in London.

i. ALIVER

The ALIVER study was funded by an €66.4 million EU Horizon 2020 grant 733057, awarded to a consortium of 11 institutions from seven countries in Europe, including Yaqrit Ltd, a spinout company from University College London that is developing the DIALIVE device and IBM Ireland Ltd, which will be applying data analytics to identify new biomarkers that can help to optimise treatment protocols. In July 2017, the first patient in the ALIVER international trial of the DIALIVE system was recruited at the Royal Free Hospital in London.
Liver Investigation: Testing Marker Utility in Steatohepatitis (LITMUS) funded by the European Innovative Medicines Initiative 2 Joint Undertaking, brings together clinicians and scientists from prominent academic centres across Europe with companies from the European Federation of Pharmaceutical Industries and Associations (EFPIA). The €34 million project is co-ordinated by Newcastle University, working closely with the lead EFPIA partner, Pfizer Ltd. LITMUS will include 47 international research partners based at leading international universities and some of the world’s largest pharmaceutical companies. EASL is proud to take part in the LITMUS project and offer dissemination assistance.

Their common goals are developing, validating and qualifying better biomarkers for testing NAFLD.

Although many people have NAFLD, less than one in 10 will come to harm as a result. The challenge is to identify those people that will be most severely affected and are going to progress to liver cirrhosis or cancer so that appropriate care can be provided earlier. At present this requires a liver biopsy, which can only be done in specialist hospitals, so there is a need for better diagnostic tools.

ACKNOWLEDGEMENTS

EASL thanks AbbVie, BMS, Gilead, and MSD for their continuous support. These collaborations are key to reducing the incidence and burden of liver disease, and we look forward to continuing our fruitful partnership to fulfil our joint mission of tackling liver disease and maximizing your presence within the hepatology arena and across other disciplines in 2018.
Report of the statutory auditor

to the General Meeting of European Association for the Study of the Liver

Zürich

Report of the statutory auditor on the financial statements

As statutory auditor, we have audited the accompanying financial statements of European Association for the Study of the Liver, which comprise the balance sheet, income statement and notes, for the year ended 31 December 2017.

Board’s responsibility

The Board is responsible for the preparation of the financial statements in accordance with the requirements of Swiss law and the association’s articles of incorporation. This responsibility includes designing, implementing and maintaining an internal control system relevant to the preparation of financial statements that are free from material misstatement, whether due to fraud or error. The Board is further responsible for selecting and applying appropriate accounting policies and making accounting estimates that are reasonable in the circumstances.

Auditor’s responsibility

Our responsibility is to express an opinion on these financial statements based on our audit. We conducted our audit in accordance with Swiss law and Swiss Auditing Standards. Those standards require that we plan and perform the audit to obtain reasonable assurance whether the financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor’s judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers the internal control system relevant to the entity’s preparation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity’s internal control system. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of accounting estimates made, as well as evaluating the overall presentation of the financial statements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Opinion

In our opinion, the financial statements for the year ended 31 December 2017 comply with Swiss law and the association’s articles of incorporation.
Report on other legal requirements

We confirm that we meet the legal requirements on licensing according to the Auditor Oversight Act (AOA) and independence (article 69b paragraph 3 CC in connection with article 728 CO) and that there are no circumstances incompatible with our independence.

We recommend that the financial statements submitted to you be approved.

PricewaterhouseCoopers SA

Marc Secretan
Audit expert
Geneva, 7 March 2018

TREASURER’S REPORT

Dear Members,

As the Treasurer of the European Association for the Study of the Liver (EASL), it is an accomplishment to provide you with the Treasurer’s Report for the 2017 Accounts.

In 2017, remarkable performances were achieved by our Association, while the Home of Hepatology activated in-depth structural and organizational improvements.

In terms of governance, 2017 has been extremely challenging and several actions have been taken until the end of year, and will be pursued in 2018, in order to meet our members and partners’ expectations.

This is the third year that The International Liver Congress TM is fully managed internally, allowing a professional and experienced in-house management of our core event, as well as reinforcing our overall statutory activities.

Over the past 9 years, we were able to constantly secure the assets of the Association, monitoring our budget with prudence, allowing us to constantly renew and improve our Research, Education and Scientific Activities for the benefit of our members. I would also like to mention our continuous efforts to support smaller conferences throughout the whole year.

In 2017, our total income increased around +20% in a year, mainly due to the repeated success of The International Liver Congress TM, stronger support from our Sponsors and The Journal of Hepatology sales. As a consequence of close monitoring of our expenses, our total net result increased about 473%.

In the last 3 years, the EASL accounts have been audited with a positive opinion by PricewaterhouseCoopers (PwC), worldwide recognized professional audit experts. Their work comprises the balance sheet, income statement and notes for the year ended, under the Swiss Code of Obligation, in accordance with Swiss law and our Constitution.

Therefore, I’m pleased to confirm again this year that our Association is in a healthy financial situation and ready to face the extraordinary challenges to come within the liver disease sector.
### EASL

**EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER**


#### BUDGET

<table>
<thead>
<tr>
<th>INCOME</th>
<th>2015</th>
<th>2016</th>
<th>2016</th>
<th>VAR. %</th>
<th>2017</th>
<th>2017</th>
<th>VAR. %</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>FINAL</td>
<td>BUDGET</td>
<td>FINAL</td>
<td>2016 VS BUDGET</td>
<td>FINAL</td>
<td>BUDGET</td>
<td>2017 VS BUDGET</td>
</tr>
<tr>
<td>ILC RESULT [PNL]</td>
<td>2,909</td>
<td>2,900</td>
<td>2,786</td>
<td>-114 -4%</td>
<td>2,851</td>
<td>3,895</td>
<td>1,044 37%</td>
</tr>
<tr>
<td>INCOME</td>
<td>7,934</td>
<td>7,500</td>
<td>7,579</td>
<td>79 1%</td>
<td>7,695</td>
<td>8,459</td>
<td>764 10%</td>
</tr>
<tr>
<td>EXPENSES (EXCLUDING STAFF COST)</td>
<td>-5,025</td>
<td>-4,600</td>
<td>-4,793</td>
<td>+193 4%</td>
<td>-4,844</td>
<td>-4,564</td>
<td>280 -6%</td>
</tr>
<tr>
<td>GRANTS &amp; SPONSORS REVENUE</td>
<td>811</td>
<td>857</td>
<td>842</td>
<td>-15 -2%</td>
<td>1,053</td>
<td>1,067</td>
<td>14 1%</td>
</tr>
<tr>
<td>EDUCATIONAL GRANTS &amp; SPONSORS</td>
<td>750</td>
<td>800</td>
<td>785</td>
<td>-15 -2%</td>
<td>996</td>
<td>997</td>
<td>1 0%</td>
</tr>
<tr>
<td>UEG SUPPORT</td>
<td>57</td>
<td>57</td>
<td>57</td>
<td>- -</td>
<td>57</td>
<td>57</td>
<td>- -</td>
</tr>
<tr>
<td>OTHERS SUPPORT (GMC)</td>
<td>4</td>
<td>-</td>
<td>-</td>
<td>- -</td>
<td>-</td>
<td>13</td>
<td>13 -</td>
</tr>
<tr>
<td>JOURNAL RESULT [PNL]</td>
<td>712</td>
<td>669</td>
<td>905</td>
<td>236 35%</td>
<td>760</td>
<td>832</td>
<td>72 9%</td>
</tr>
<tr>
<td>INCOME</td>
<td>1,013</td>
<td>975</td>
<td>1,219</td>
<td>244 25%</td>
<td>1,148</td>
<td>1,124</td>
<td>-24 -2%</td>
</tr>
<tr>
<td>JOURNAL ROYALTIES</td>
<td>561</td>
<td>511</td>
<td>712</td>
<td>201 39%</td>
<td>641</td>
<td>651</td>
<td>10 2%</td>
</tr>
<tr>
<td>EDITORIAL OFFICE SUPPORT</td>
<td>412</td>
<td>424</td>
<td>460</td>
<td>36 8%</td>
<td>467</td>
<td>433</td>
<td>-34 -7%</td>
</tr>
<tr>
<td>SIGNING B. OTHERS (200K€ / 5+)</td>
<td>40</td>
<td>40</td>
<td>47</td>
<td>7 17%</td>
<td>40</td>
<td>40</td>
<td>- -</td>
</tr>
<tr>
<td>EXPENSES (excluding Staff cost)</td>
<td>-301</td>
<td>-306</td>
<td>-314</td>
<td>-8 3%</td>
<td>-388</td>
<td>-292</td>
<td>96 -25%</td>
</tr>
<tr>
<td>STAFF COSTS</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>- -</td>
<td>-</td>
<td>-</td>
<td>- -</td>
</tr>
<tr>
<td>CONSULTANCY / HONORARIUM</td>
<td>-269</td>
<td>-267</td>
<td>-272</td>
<td>-5 2%</td>
<td>-346</td>
<td>-288</td>
<td>58 -17%</td>
</tr>
<tr>
<td>OFFICE OVERHEADS / APPS</td>
<td>-32</td>
<td>-39</td>
<td>-42</td>
<td>-3 8%</td>
<td>-42</td>
<td>-4</td>
<td>38 -90%</td>
</tr>
<tr>
<td>MEMBERSHIP REVENUE</td>
<td>593</td>
<td>665</td>
<td>697</td>
<td>32 5%</td>
<td>762</td>
<td>694</td>
<td>-68 -9%</td>
</tr>
<tr>
<td>OTHERS REVENUE (VAT)</td>
<td>52</td>
<td>-</td>
<td>106</td>
<td>106 -</td>
<td>52</td>
<td>106</td>
<td>- -</td>
</tr>
<tr>
<td>FINANCIAL REVENUE</td>
<td>570</td>
<td>406</td>
<td>411</td>
<td>5 1%</td>
<td>334</td>
<td>417</td>
<td>83 25%</td>
</tr>
<tr>
<td>------------------------------</td>
<td>------------</td>
<td>-------------</td>
<td>------------</td>
<td>----------------------------------</td>
<td>------------</td>
<td>------------</td>
<td>----------------------------------</td>
</tr>
<tr>
<td>EXPENSES</td>
<td>5,051</td>
<td>5,308</td>
<td>4,868</td>
<td>-41 -8%</td>
<td>5,524</td>
<td>5,553</td>
<td>+29 +1%</td>
</tr>
<tr>
<td>• EASL RESEARCH GRANTS</td>
<td>601</td>
<td>664</td>
<td>660</td>
<td>-4 -1%</td>
<td>649</td>
<td>591</td>
<td>-58 -9%</td>
</tr>
<tr>
<td>EASL REGISTRY GRANTS</td>
<td>150</td>
<td>150</td>
<td>150</td>
<td>- -</td>
<td>150</td>
<td>150</td>
<td>- -</td>
</tr>
<tr>
<td>FELLOWSHIPS &amp; MENTORSHIPS</td>
<td>451</td>
<td>514</td>
<td>510</td>
<td>-4 -1%</td>
<td>499</td>
<td>441</td>
<td>-58 -12%</td>
</tr>
<tr>
<td>• BUSINESS CHARGES</td>
<td>447</td>
<td>425</td>
<td>470</td>
<td>45 11%</td>
<td>440</td>
<td>455</td>
<td>15 3%</td>
</tr>
<tr>
<td>GOVERNANCE (HONORARIUM)</td>
<td>90</td>
<td>90</td>
<td>90</td>
<td>- -</td>
<td>90</td>
<td>108</td>
<td>18 20%</td>
</tr>
<tr>
<td>PROMOTION - SISTER SOCIETIES</td>
<td>122</td>
<td>145</td>
<td>165</td>
<td>20 14%</td>
<td>153</td>
<td>133</td>
<td>-20 -13%</td>
</tr>
<tr>
<td>COMMITTEES (BOARD/CAG/CPG...)</td>
<td>31</td>
<td>52</td>
<td>44</td>
<td>-8 -15%</td>
<td>39</td>
<td>75</td>
<td>36 92%</td>
</tr>
<tr>
<td>EUROPEAN ADVOCACY &amp; MEETINGS</td>
<td>205</td>
<td>138</td>
<td>171</td>
<td>33 24%</td>
<td>158</td>
<td>139</td>
<td>-19 -12%</td>
</tr>
<tr>
<td>• NON-BUSINESS CHARGES</td>
<td>312</td>
<td>364</td>
<td>307</td>
<td>-57 -16%</td>
<td>389</td>
<td>729</td>
<td>340 87%</td>
</tr>
<tr>
<td>EDUCATION E-TOOLS &amp; E-LEARNING</td>
<td>86</td>
<td>210</td>
<td>140</td>
<td>-70 -33%</td>
<td>182</td>
<td>186</td>
<td>4 2%</td>
</tr>
<tr>
<td>MARKETING &amp; COMMUNICATION</td>
<td>114</td>
<td>61</td>
<td>64</td>
<td>3 5%</td>
<td>75</td>
<td>38</td>
<td>-37 -49%</td>
</tr>
<tr>
<td>LEGAL, FINANCE &amp; CONSULTANCY</td>
<td>113</td>
<td>93</td>
<td>103</td>
<td>10 11%</td>
<td>132</td>
<td>505</td>
<td>373 283%</td>
</tr>
<tr>
<td>• SHARED SERVICES (OFFICE)</td>
<td>2,903</td>
<td>3,154</td>
<td>3,100</td>
<td>-54 -2%</td>
<td>3,439</td>
<td>3,339</td>
<td>-100 -3%</td>
</tr>
<tr>
<td>STAFF COSTS</td>
<td>2,593</td>
<td>2,853</td>
<td>2,770</td>
<td>-83 -3%</td>
<td>3,100</td>
<td>2,963</td>
<td>-137 -4%</td>
</tr>
<tr>
<td>ALL OVERHEADS (IT/TRAVELS/MEALS)</td>
<td>240</td>
<td>187</td>
<td>216</td>
<td>29 16%</td>
<td>206</td>
<td>264</td>
<td>58 28%</td>
</tr>
<tr>
<td>CRM</td>
<td>70</td>
<td>114</td>
<td>114</td>
<td>- -</td>
<td>133</td>
<td>101</td>
<td>-32 -24%</td>
</tr>
<tr>
<td>BUILDING CHARGES</td>
<td>789</td>
<td>701</td>
<td>330</td>
<td>-371 -53%</td>
<td>607</td>
<td>439</td>
<td>-168 -28%</td>
</tr>
<tr>
<td>• EASL SMALL CONFERENCES</td>
<td>375</td>
<td>341</td>
<td>312</td>
<td>-129 -38%</td>
<td>367</td>
<td>316</td>
<td>-51 -14%</td>
</tr>
<tr>
<td>MONOTHEMATIC CONFERENCES</td>
<td>103</td>
<td>35</td>
<td>-175</td>
<td>-210 -600%</td>
<td>-63</td>
<td>-119</td>
<td>-56 89%</td>
</tr>
<tr>
<td>SPECIAL CONFERENCES (HCC 2017)</td>
<td>115</td>
<td>135</td>
<td>95</td>
<td>-40 -30%</td>
<td>90</td>
<td>58</td>
<td>-32 -36%</td>
</tr>
<tr>
<td>BASIC SCHOOLS</td>
<td>59</td>
<td>65</td>
<td>65</td>
<td>- -</td>
<td>60</td>
<td>59</td>
<td>-1 -2%</td>
</tr>
<tr>
<td>YI MASTERCLASS</td>
<td>137</td>
<td>125</td>
<td>134</td>
<td>9 7%</td>
<td>153</td>
<td>125</td>
<td>-28 -18%</td>
</tr>
<tr>
<td>NET RESULT</td>
<td>596</td>
<td>189</td>
<td>880</td>
<td>+691 +366%</td>
<td>236</td>
<td>1,352</td>
<td>+1,116 +473%</td>
</tr>
</tbody>
</table>